Summary
Fifty-one salivary gland tumours (23 pleomorphic adenomas, 5 Warthin's tumours, 12 mucoepidermoid carcinomas, 7 adenoid cystic carcinomas, 3 undifferentiated carcinomas and 1 acinic cell tumour) and 27 lung carcinomas (18 squamous cell carcinomas, 6 adenocarcinomas and 3 small cell carcinomas) were analysed immunohistochemically for the expression ofp53 nuclear phosphoprotein. Eight out of 51 (16%) salivary gland tumours werep53 positive. Three of these were benign and 5 malignant. All 3 benign salivary gland tumours were pleomorphic adenomas and expressed only occasional nuclear positivity with less than 1% of tumour cells positive. Of the 5p53-positive malignant tumours, 3 were mucoepidermoid carcinomas and 2 undifferentiated carcinomas. The malignant salivary gland tumours expressed more than 1% of positive nuclei in every case. Seventeen lung carcinomas werep53 positive (63%). Thirteen of these were squamous cell carcinomas, 3 were adenocarcinomas and 1 small cell lung carcinoma. The results show that mutations of thep53 gene may be infrequent in salivary gland tumours when compared with lung carcinomas. The relatively indolent course of some histological types of malignant salivary gland tumours could be associated with the preservation of the non-mutatedp53 gene in most of these tumours. The presence ofp53 positivity in some pleomorphic adenomas might, on one hand, suggest thatp53 gene alterations are also present in these tumours; on the other hand, the accumulation of thep53 protein in these tumours might also be due to some unknown mechanism, not necessarily related top53 gene mutation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baker SJ, Fearon EJ, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, Tuinen P van, Ledbetter DH, Barker DF, Nakamura Y, White R, Vogelstein B (1989) Chromosome 17 deletions andp53 gene mutations in colorectal carcinomas. Science 244:217–221
Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV, Lane DP (1991) Aberrant expression of thep53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6:1699–1703
Bartkova J, Bartek J, Lukas J, Voitesek B, Staskova Z, Rejthar A, Kovarik J, Midgley CA, Lane DP (1991)p53 protein alterations in human testicular cancer including pre-invasive intratubular germ-cell neoplasia. Int J Cancer 49:196–202
Bischoff JR, Friedman PN, Marshak DR, Prives C, Beach D (1990) Humanp53 is phosphorylated by p64-cdc2 and cyclin B-cdc2. Proc Natl Acad Sci USA 87:4766–4770
Caamano J, Ruggeri B, Momiki S, Sickler A, Zhang SY, Klein-Szanto AJP (1991) Detection ofp53 in primary lung tumors and nonsmall cell lung carcinoma cell lines. Am J Pathol 139:839–845
Campo E, Calle-Martin O de la, Miguel R, Palacin A, Romero M, Fabregat V, Vivers J, Cardesa A, Yague J (1991) Loss of heterozygosity ofp53 gene andp53 protein expression in human colorectal carcinomas. Cancer Res 51:4436–4442
Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D (1988)p53 expression in breast cancer. Int J Cancer 41:178–183
Chiba I, Takahashi T, Nau MM, D'Amico D, Curiel DT, Mutsudomi T, Buchhagen DL, Carbone D, Piantadosi S, Koga H, Reissman PT, Slamon DJ, Holmes EC, Minna JD (1990) Mutations in thep53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 5:1603–1610
Deppert W, Buschhausen-Denker G, Patschinsky T, Steinmeyer K (1990) Cell cycle control ofp53 in normal (3T3) and chemically transformed (Meth A) mouse cells. II. Requirement for cell cycle progression. Oncogene 5:1701–1706
Farrell PJ, Allan GJ, Shanahan F, Vousden KH, Crook T (1991)p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J 10:2879–2887
Finlay CA, Hinds PW, Tan T-H, Eliyahu D, Oren M, Levine J (1988) Activating mutations for transformation byp53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8:531–539
Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla-Favera R (1991)p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88:5413–5417
Hollstein M, Sidransky D, Vogelstein B, Harris C (1991)p53 mutations in human cancers. Science 253:49–53
Hsu SM, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 29:577–580
Iggo R, Gatter K, Bartek J, Lane D, Harris AL (1990) Increased expression of mutant forms ofp53 oncogene in primary lung cancer. Lancet 335:675–679
Lane D, Benchimol S (1990)p53: oncogene or anti-oncogene. Gene 4:1–8
Lavigueur A, Maltby V, Mock D, Rossant J, Pawson T, Bernstein A (1989) High incidence of lung, bone, and lymphoid tumours in transgenic mice overexpressing mutant alleles of thep53 oncogene. Mol Cell Biol 9:3989–3991
Mashiyama S, Murakami Y, Yoshimoto T, Sekiya T, Hayashi K (1991) Detection ofp53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 6:1313–1318
Masuda H, Miller C, Koeffler HP, Battifora H, Cline MJ (1987) Rearrangement of thep53 gene in human osteogenic sarcomas. Proc Natl Acad Sci USA 84:7716–7719
Mercer WE, Baserga R (1985) Expression of thep53 protein during the cell cycle of human peripheral blood lymphocytes. Exp Cell Res 160:31–46
Mercer WE, Avignolo C, Basegra R (1984) Role ofp53 protein in cell proliferation as studied by microinjection of monoclonal antibodies. Mol Cell Biol 4:276–281
Midgley CA, Fisher CJ, Bartek J, Vojtesek B, Lane D, Barnes DM (1992) Expression of humanp53 in bacteria: application to the analysis ofp53 expression in human tumours. J Cell Sci 101:183–189
Miller C, Mohandas T, Wolf D, Prokocimer M, Rotter V, Koeffler HP (1986) Humanp53 gene localized to short arm of chromosome 17. Nature 319:783–784
Milner J (1991) The role ofp53 in normal control of cell proliferation. Curr Opin Cell Biol 3:282–286
Mulligan LM, Matlashewski GJ, Scrable HJ, Cavenee WK (1990) Mechanisms ofp53 loss in human sarcomas. Proc Natl Acad Sci USA 87:5863–5867
Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Clearly K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B (1989) Mutations in thep53 gene occur in diverse human tumour types. Nature 342:705–708
Prosser J, Thompson AM, Cranston G, Evans HJ (1990) Evidence thatp53 behaves as a tumour suppressor gene in sporadic breast tumours. Oncogene 5:1573–1579
Purdie CA, O'Grady J, Piris J, Wyllie AH, Bird CC (1991)p53 expression in colorectal tumors. Am J Pathol 138:807–813
Soini Y, Pääkkö P, Alavaikko M, Vähäkangas K (1992a)p53 expression in lymphatic malignancies. J Clin Pathol 45 (in press)
Soini Y, Pääkkö P, Nuorva K, Kamel D, Lane DP, Vähäkangas K (1992b) Comparative analysis ofp53 protein immunoreactivity in prostatic, lung and breast carcinomas. Virchows Arch [A] (in press)
Soini Y, Vähäkangas K, Nuorva K, Kamel D, Lane DP, Pääkkö P (1992c)p53 immunohistochemistry in malignant fibrous histiocytomas and other mesenchymal tumours. J Pathol 168 (in press)
Steinmeyer K, Maacke H, Deppert W (1990) Cell cycle control byp53 in normal (3T3) and chemically transformed (Meth A) mouse cells. I. Regulation ofp53 expression. Oncogene 5:1691–1699
Stratton MR, Moss S, Warren W, Patterson H, Clark J, Fisher C, Fletcher CDM, Ball A, Thomas M, Gusterson BA, Cooper CS (1990) Mutation of thep53 gene in human soft tissue sarcomas: association with abnormalities of theRB1 gene. Oncogene 5:1297–1301
Thackray AC, Lucas RB (1974) Tumors of the major salivary glands. Atlas of tumor pathology, 2nd series, fascicle 10. Armed Forces Institute of Pathology, Bethesda, pp 69–99
Thompson AM, Steel CM, Chetty U, Hawkins RA, Miller WR, Carter DC, Forrest APM, Evans HJ (1990)p53 gene mRNA expression and chromosome17p allele loss in breast cancer. Br J Cancer 61:74–78
Vogelstein B (1989) Chromosome17 deletions andp53 gene mutations in colorectal carcinomas. Science 244:217–221
Wagner P, Simanis V, Maimets T, Keenan E, Addison C, Brain R, Grimaldi M, Sturzbecher HW, Jenkins J (1991) A human tumour-derived mutantp53 protein induces a p34cdc2 reversible growth arrest in fission yeast. Oncogene 6:1539–1547
Winman KG, Magnusson KP, Ramqvist T, Klein G (1991) Mutantp53 detected in a majority of Burkitt lymphoma cell lines by monoclonal antibody PAb240. Oncogene 6:1633–1639
World Health Organization (1981) Histological typing of lung tumours. International classification of tumours no. 1. World Health Organization, Geneva
World Health Organization (1991) Histological typing of salivary gland tumours. International histological classification of tumours no. 7, 2nd edn. World Health Organization, Geneva
Wright PA, Lemoine NR, Goretzki PE, Wyllie FS, Bond J, Hughes C, Röher H-D, Williams ED, Wynford-Thomas D (1991) Mutations of thep53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumors. Oncogene 6:1693–1697
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Soini, Y., Kamel, D., Nuorva, K. et al. Lowp53 protein expression in salivary gland tumours compared with lung carcinomas. Vichows Archiv A Pathol Anat 421, 415–420 (1992). https://doi.org/10.1007/BF01606914
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01606914